Allarity Therapeutics, Inc. held its annual meeting on June 26, 2026, where stockholders approved the election of Jesper Hoiland, the ratification of Wolf & Company, P.C. as independent auditors, an increase in the 2021 Equity Incentive Plan share authorization to 2,021,990, advisory executive compensation, and the issuance of shares to Tumim Stone Capital LLC in excess of the Exchange Cap. A proposal to limit officer liability via an amendment to the Certificate of Incorporation failed to pass. Additionally, the company announced on June 30, 2026, that the USPTO granted a U.S. patent for its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. Allarity Therapeutics is a biotechnology company developing precision medicines.

Allarity Therapeutics announced the presentation of a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026, held June 17–19, 2026, in Copenhagen, Denmark. The company operates in the biotechnology industry and develops therapeutic treatments for cancer.